Apimeds Pharmaceuticals US, Inc. (NYSE American: APUS) has engaged IBN to assist with its corporate communications strategy, according to a press release. The move is designed to generate greater awareness for the clinical-stage biopharmaceutical company and its wholly owned subsidiary, MindWave Innovations, which is developing institutional digital asset infrastructure.
IBN will leverage its investor-focused distribution network, including more than 5,000 syndication outlets, newsletters, social media channels, InvestorWire, and other outreach tools, to amplify Apimeds' message. The partnership aims to connect the company with a broad audience of investors, influencers, consumers, journalists, and the general public.
Apimeds Pharmaceuticals US, Inc. is a clinical-stage biopharmaceutical company focused on developing non-opioid, biologic-based therapies for pain management. Its subsidiary, MindWave Innovations Inc., is building enterprise blockchain infrastructure and institutional technology platforms through its MindChain ecosystem, which combines insured custody, transparent reporting, and technology-driven portfolio management to support risk-aware yield on Bitcoin reserves and institutional participation in the digital asset economy.
The MindChain ecosystem operates four distinct verticals: InsurTech through BlockAssure, which is developing a Bermuda-framework platform applying Bitcoin reserves as regulatory capital to support life and property and casualty underwriting; ClimateTech through AQUAE and the ALCI index, measuring, verifying, and tokenizing ecosystem services into institutional-grade assets; HealthTech through the Apitox development program; and RWA Tech through Nexus Global Partners, bringing institutional real estate on-chain within a compliance-first, insurance-enhanced framework.
This engagement matters because it signals Apimeds' intent to raise its profile within the investment community, potentially attracting more investor attention to its dual focus on biopharmaceuticals and blockchain technology. For readers and industry observers, the partnership underscores the growing convergence of traditional healthcare and digital asset infrastructure, a trend that could reshape how institutional investors allocate capital and manage risk.
To view the full press release, visit https://ibn.fm/PdvmC. For more information about Apimeds Pharmaceuticals US, Inc., visit www.ApimedsUS.com. The latest news and updates relating to APUS are available in the company's newsroom at https://ibn.fm/APUS.
